Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Lung Neoplasms 2Recurrence 1Non-Small Cell Lung Cancer ALK-positive 1Neurofibromatosis 1 1Neoplasm Metastasis 1Meningeal Carcinomatosis 1Hereditary Sensory and Autonomic Neuropathies 1Glioma 1Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1Brain Neoplasms 1Astrocytoma 1Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer 1Advanced Non-Small Cell Lung Cancer 1ALK Positive Non-small Cell Lung Cancer 1

Interventions

Temozolomide 3Specimen Handling 2tovorafenib 1spartalizumab 1ribociclib 1pembrolizumab 1lutetium Lu 177 dotatate 1lorlatinib 1larotrectinib 1balstilimab 1Vaccines 1Receptors, Interleukin-8B 1Radiotherapy 1Pharmacogenomic Variants 1Pharmacogenomic Testing 1PTC596 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Injections 1Immune Checkpoint Inhibitors 1Fluid Therapy 1Everolimus 1Eflornithine 1Diphtheria-Tetanus Vaccine 1Diffusion Tensor Imaging 1Cilengitide 1CLR1404 1CBLC137 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Diffuse Intrinsic Pontine Glioma × lorlatinib × 90 days × Clear all
NCT06333899 2026-03-12

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

Nationwide Children's Hospital

Phase EARLY_PHASE1 Recruiting
15 enrolled
CNS

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡